Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Oral extended-release tablets and the monthly SUSTENNA injection are separate product sections. No regimen is inferred for 3- or 6-month injections.
Check source scope before reading a dose
GlobalRPh RX List - INVEGA tablets
Product / population
Adult oral paliperidone extended-release tablets; not a long-acting injection.
Renal method
CrCl in mL/min.
Source revision
February 2017
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
GlobalRPh-hosted RX List · Adult oral paliperidone extended-release tablets; not a long-acting injection.
Renal method: CrCl in mL/min. Source date: February 2017 Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
At CrCl 50 to under 80 mL/min, start 3 mg once daily; the maximum is 6 mg daily after response/tolerability assessment. At CrCl 10 to under 50, start 1.5 mg once daily, with a maximum of 3 mg daily after reassessment. Use below 10 is not recommended because it was not studied. Swallow ER tablets intact. These oral instructions must not be transferred to long-acting injectable paliperidone.
RDM43-rxlist-paliperidone-6c926a5b53-C1 · Source locator: Selected Dosage / Renal Impairment / Warnings sections; see source-specific qualifications in this summary.
Source-specific limits
Independently opened product page after the directory-link tool failed; exact I-index href was not verified.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.